These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31552470)

  • 1. Resolution of Crohn's disease.
    Schmitt H; Neufert C; Neurath MF; Atreya R
    Semin Immunopathol; 2019 Nov; 41(6):737-746. PubMed ID: 31552470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the IL23/IL17 Pathway in Crohn's Disease.
    Schmitt H; Neurath MF; Atreya R
    Front Immunol; 2021; 12():622934. PubMed ID: 33859636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
    Billmeier U; Dieterich W; Neurath MF; Atreya R
    World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in understanding the role of cytokines in inflammatory bowel disease.
    Bevivino G; Monteleone G
    Expert Rev Gastroenterol Hepatol; 2018 Sep; 12(9):907-915. PubMed ID: 30024302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.
    Schreiber S; Nikolaus S; Hampe J; Hämling J; Koop I; Groessner B; Lochs H; Raedler A
    Lancet; 1999 Feb; 353(9151):459-61. PubMed ID: 9989717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA.
    Piñero P; Juanola O; Gutiérrez A; Zapater P; Giménez P; Steinert A; Sempere L; González-Navajas JM; Niess JH; Francés R
    J Mol Med (Berl); 2017 Nov; 95(11):1227-1236. PubMed ID: 28879509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
    Bauditz J; Haemling J; Ortner M; Lochs H; Raedler A; Schreiber S
    Gut; 1997 Apr; 40(4):470-4. PubMed ID: 9176073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated review on immune factors in pathogenesis of Crohn's disease.
    Li N; Shi RH
    World J Gastroenterol; 2018 Jan; 24(1):15-22. PubMed ID: 29358878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
    Bassolas-Molina H; Raymond E; Labadia M; Wahle J; Ferrer-Picón E; Panzenbeck M; Zheng J; Harcken C; Hughes R; Turner M; Smith D; Calderón-Gómez E; Esteller M; Carrasco A; Esteve M; Dotti I; Corraliza AM; Masamunt MC; Arajol C; Guardiola J; Ricart E; Nabozny G; Salas A
    Front Immunol; 2018; 9():2307. PubMed ID: 30405600
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Crohn's disease: a still tourbillon of etiopathogenetic theories and therapeutic strategies. Some implications in the field of urology].
    Alberti C
    G Chir; 2010 Mar; 31(3):124-33. PubMed ID: 20426926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine therapies in Crohn's disease: where are we now and where should we go?
    Caprioli F; Pallone F; Monteleone G
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):47-53. PubMed ID: 21184652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.
    Brand S
    Gut; 2009 Aug; 58(8):1152-67. PubMed ID: 19592695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cell adhesion molecules in evaluation of Crohn's disease therapy].
    Lazebnik LB; Boldyreva ON; Parfenov AI; Trubitsyna IE; Shcherbakov PL; Khomeriki SG; Kniazev OV; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (3):31-8. PubMed ID: 24294769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.
    Shetty A; Forbes A
    Am J Pharmacogenomics; 2002; 2(4):215-21. PubMed ID: 12421092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.